DUBLIN--(BUSINESS WIRE)--The "Generalized Tonic-Clonic Seizure Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering. Generalized Tonic-Clonic ...
-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — Primary generalized tonic-clonic seizures ...
FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 ...
February 4, 2010 — The US Food and Drug Administration (FDA) has approved an expanded indication for lamotrigine extended-release tablets (Lamictal XR, GlaxoSmithKline) as once-daily adjunctive ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The study included 426 women with IGE or tonic-clonic ...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant ...
-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- The PMA-S is ...
WASHINGTON -- Technologies to provide instant at-home detection of life-threatening seizures and that could allow epilepsy patients to monitor their own drug levels are on the horizon, researchers ...
Eisai announced results from a Phase 3 Study 332 trial of perampanel, an AMPA receptor antagonist in patients with primary generalized tonic-clonic (PGTC) seizures. Study 332 was a double-blind, ...
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results